Quetiapine Fumarate
FDA-approved product (tablet, oral), marketed as Quetiapine Fumarate, Seroquel, Seroquel Xr.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bipolar disorder
- Bipolar I disorder
- Bipolar II disorder
- Major depressive disorder
- Psychosis
- Schizoaffective disorder
- Schizophrenia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Diazepines, oxazepines, thiazepines and oxepines
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA31.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli46.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis52.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Quetiapine Fumarate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Ozanimod HydrochlorideExisting use: Multiple sclerosis, Relapsing-remitting multiple sclerosis, Ulcerative colitis66.8% AI-predicted activityagainst MRSA7 registered studies
- Micafungin SodiumExisting use: Candidiasis66.8% AI-predicted activityagainst MRSA50+ registered studies
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- Lazertinib MesylateExisting use: Non-small cell lung carcinoma66.1% AI-predicted activityagainst MRSANo documented evidence found
- Desmopressin AcetateExisting use: Central diabetes insipidus, Diabetes insipidus, Enuresis and 5 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia65.8% AI-predicted activityagainst MRSA41 registered studies
- VemurafenibExisting use: Cancer, Cutaneous melanoma, Melanoma and 2 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more65.5% AI-predicted activityagainst MRSA50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm65.5% AI-predicted activityagainst MRSA50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more65.4% AI-predicted activityagainst MRSA5 registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more65.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Comparison of Two Standard Therapies in the Management of Dementia With Agitation
NCT00208819 · start 2003-09
Registered record
- Registry ID
- NCT00208819
- Conditions
- Senile Dementia, Alzheimer Type; Dementia, Alzheimer Type; Alzheimer Disease; Dementia
- Interventions
- risperidone; quetiapine; olanzapine; divalproex
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2003-09
- Completion
- 2007-07
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSenile Dementia, Alzheimer Type; Dementia, Alzheimer Type; Alzheimer Disease; DementiaInterventionrisperidone; quetiapine; olanzapine; divalproexPhasePhase 4Registry statusCompletedQuetiapine Treatment for Post-Traumatic Stress Disorder (PTSD)
NCT00237393 · start 2003-08
Registered record
- Registry ID
- NCT00237393
- Conditions
- PTSD
- Interventions
- Quetiapine; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2003-08
- Completion
- 2007-12
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPTSDInterventionQuetiapine; PlaceboPhasePhase 4Registry statusCompletedA Comparative Study of New Medications for Psychosis in Adolescents
NCT00222495 · start 2002-08
Registered record
- Registry ID
- NCT00222495
- Conditions
- Psychotic Disorders; Schizophrenia; Schizophreniform Disorders; Schizoaffective Disorders
- Interventions
- quetiapine; olanzapine; risperidone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2002-08
- Completion
- 2006-08
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPsychotic Disorders; Schizophrenia; Schizophreniform Disorders; Schizoaffective DisordersInterventionquetiapine; olanzapine; risperidonePhaseNot applicableRegistry statusCompletedEffect of Quetiapine on Negative Symptoms and Cognition
NCT00305422 · start 2001-11
Registered record
- Registry ID
- NCT00305422
- Conditions
- Schizophrenia
- Interventions
- Quetiapine fumarate; Risperidone
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2001-11
- Completion
- 2003-01
- Enrolment
- 45
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionQuetiapine fumarate; RisperidonePhasePhase 3Registry statusCompletedCATIE- Schizophrenia Trial
NCT00014001 · start 2000-12
Registered record
- Registry ID
- NCT00014001
- Conditions
- Schizophrenia
- Interventions
- perphenazine; olanzapine; quetiapine; risperidone; ziprasidone; clozapine; fluphenazine decanoate
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2000-12
- Completion
- 2004-12
- Enrolment
- 1,600
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionperphenazine; olanzapine; quetiapine; risperidone +3 morePhasePhase 4Registry statusCompleted